Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Mesalazine is used to treat inflammatory bowel disease
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
Investment will fund expansion to meet rising demand for CRDMO services
Acquisition expands high-value medical platform
Subscribe To Our Newsletter & Stay Updated